Literature DB >> 12915339

Long-term experience with levetiracetam.

Bassel Abou-Khalil1, Barry Lazenby.   

Abstract

Although short-term clinical trials provide important data regard-ing efficacy and tolerability, long-term studies are needed to address important aspects of clinical practice, such as long-term efficacy and safety. Long-term studies and post-marketing data show that the efficacy of levetiracetam is sustained over the long term and that this antiepileptic drug continues to be well tolerated, with low withdrawal rates and high retention rates. Patients continue to achieve significant reductions in seizure frequency and may achieve seizure freedom. Levetiracetam may allow patients to decrease the number of concomi-tant antiepileptic medications or withdraw to monotherapy. Add-on therapy with levetiracetam should be considered when additional control of seizures is needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915339

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  3 in total

Review 1.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

3.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.